RevCAR-modified and RevTM-redirected T cells were highly effective in eliminating various cancer cells expressing different TAAs in vitro and using mouse tumor models [186], including patient-derived AML cells expressing CD33 and CD123 [187] and glioblastoma cells [188]. The gene discussed is CD33; the disease is acute myeloid leukemia.